Brought to you by 
Series C leads to $55mm for Phenomix
13 Mar 2007
Executive Summary
Phenomix (has programs in immunology, cancer, infectious diseases, and metabolic disorders) raised $55mm in its Series C financing led by first-time backer Nomura Phase4 Ventures. Returning shareholders JP Morgan Partners, Delphi Ventures, Baker Brothers, Alta Partners, Sofinnova Ventures, Bay City Capital, CMEA Ventures, Novartis BioVenture Fund, and GBS Venture Partners also participated. The company will use the funds for ongoing Phase II clinical trials of its diabetes compound and to continue developing its preclinical HCV candidate. A member of Nomura will take a seat on Phenomix's board.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- ADMET
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series C leads to $55mm for Phenomix
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice